Dexcom

A Deep Dive into Continuous Glucose Monitoring Use in Primary Care with Dexcom Clarity Software


Presented by: Davida Kruger, MSN, APN-BC, BC-ADM

Primary Care: Important to the Management of Diabetes

Distributions of Endocrinologists/Diabetologists and Primary Care Providers Across the United States

US Counties with ≥ 1
Pediatric or Adult Endocrinologist/Diabetologist

US Counties with ≥ 1 Primary Care Provider



CGM Technology Enhances Existing Models of Care





Diabetes care that relies on quarterly visits with A1C checks neglects the reality of life with diabetes that is continuous¹



Using A1C alone may not be very helpful to patients for understanding their diabetes²

- Impact of lifestyle on glycemic management
- No visibility on their response to interventions
- May be reluctant to advance therapy if they don't understand their glycemic pattern



Blood glucose monitoring (BGM) has notable limitations³

- Measures blood glucose (BG) at a single point in time
- Patient engagement and use is impacted by associated pain and social stigma



The majority of diabetes care transpires between visits, outside of clinical encounters¹




Wearing CGM allows for personal discovery as patients engage in their own care


^{1.} Corathers S et al. Diabetes Spectrum. 2020 Feb; 33(1):22-30. 2. AACE Consensus Guidelines. Endocr Prac. 2020;26(1):107-139.

^{3.} Adolfsson P et al. *Eur Endocrinol*. 2018;14(1):24-29.


Same A1C, but CGM Patterns Drive Different Treatment Plans


A1C 7%





A1C 7%





Benefits of Real-Time Continuous Glucose Monitoring (RT-CGM)



ADA Standards of Care 2022¹




AACE Clinical practice guideline 2021²



RT-CGM continuous glucose monitoring
(A) or IS-CGM (B) **should be offered**for diabetes management in adults with
diabetes on MDI or CSII



Initiation of CGM, CSII and/or AID **early** in the treatment of diabetes can be beneficial. (C)





CGM may be recommended for individuals with T2D who are treated with less intensive insulin therapy[†]

Updated Recommendations from American Diabetes Association



ADA Standards of Care 2022¹



Initiation of CGM (CSII and/or AID)
early in the treatment of diabetes can
be beneficial depending on a
person's/caregiver's needs and
preferences (C)



Periodic use of CGM (RT-CGM, IS-CGM or Pro CGM) can be helpful for diabetes management in circumstances where continuous use of CGM is not desired or available (C)



Real-time CGM (A) or IS-CGM (C) can be used for diabetes management in adults with diabetes on basal insulin.

Overview Dexcom G6

Dexcom G6 Overview

The only CGM system indicated for children aged 2 years and older

- Up to 288 continuous readings per day
- Exceptional accuracy
- Class II device designation¹
- Zero fingersticks required,*

*If your glucose alerts and readings from the G6 do not match symptoms or expectations, use a blood glucose meter to make diabetes treatment decisions



- Customizable alerts and a fixed Urgent Low alarm
- Predictive Urgent Low Soon alert
- Data share features with up to 10 followers[†]
- Robust clinical evidence of improved glycemic outcomes^{2,3}

Smart devices sold separately.

*For a list of compatible devices visit www.Dexcom.com/compatibility

Studies prove the clinical benefits of the differentiating attributes of Dexcom.^{4,5}

[†]Separate Follow app required.

^{1.} FDA. https://www.fda.gov/news-events/press-announcements/fda-authorizes-first-fully-interoperable-continuous-glucose-monitoring-system-streamlines-review. Accessed June 19, 2019. 2. Beck RW et al. *JAMA*. 2017;317(4):371-378. 3 Welsh JB et al. *Diabetes Technol Ther*. 2019;21(3):128-132. 4. Puhr S et al. *J Diabetes Sci Technol*. 2020;14(1):83-86. 5. Welsh JB et al. *Diabetes Ther*. 2019;10(2):751-755.

Randomized Controlled Trials (RCTs) Show Improved Clinical Outcomes, High Usage, and High Satisfaction Using Dexcom CGM in Diverse Populations

SENCE^{1,2} (ages 2-7)



- Reduced # of severe hypoglycemic events $(<54 \text{ mg/dL})^{1}$
- Reduced parental burden and fear of hypoglycemia¹
- Hypoglycemia reductions sustained at 52 weeks²
- 92% CGM use maintained at 52 weeks3



CITY^{3,4} (ages 14-24) MILLENNIAL⁵ (ages 16-25)



- $\sim 0.4\%$ reduction in A1C; increased TIR; high treatment satisfaction4
- 86% CGM use at 52 weeks³
- Rapid ~ 0.5% reduction in baseline A1C; significant improvements in TIR and TAR at 8 weeks⁵



DlaMonD^{6,7} (ages 25+) GOLD⁸, SILVER⁹ (ages 18+)



- ~ 1.3% and 1.4% reduction in baseline A1C in poorly controlled T1D⁶ and T2D⁷ patients, respectively
- 93% CGM use ≥6 davs/week at 24 weeks^{6,7}
- 80% decrease in severe hypoglycemia⁸
- Sustained benefits in glycemic, QoL, and satisfaction outcomes at 2.5 years9



DlaMonD¹⁰ (ages 60+) WISDM^{11,12} (ages 60+)



- ~ 0.9% reduction in baseline A1C in seniors with T1D and T2D¹⁰
- High treatment satisfaction¹⁰
- 97% CGM use ≥6 days/week at 24 weeks¹⁰
- · Rapid decrease in time spent <70 mg/dL, TIR increased by 2.1 hrs/day.11 Glycemic benefits sustained at 52 weeks¹²

^{1.} DiMeglio LA et al: Strategies to Enhance New CGM Use in Early Childhood (SENCE) Study Group. A randomized clinical trial assessing continuous glucose monitoring (CGM) use with standardized education with or without a family behavioral intervention compared with finger-stick blood glucose monitoring in very young children with type 1 diabetes. Diabetes Care. 2020 Dec 17:dc201060. doi: 10.2337/dc20-1060. Epub ahead of print. PMID: 33334807. 2. Data presented at ADA Virtual June 12-16, 2020. Van Name M et al. Benefit of reduced hypoglycemia with continuous glucose monitoring is sustained through 12 months among young children with type 1 diabetes. 3. Data presented at ADA Virtual June 12-16, 2020. DeSalvo D et al. Durability of continuous glucose monitoring use in young adults with type 1 diabetes. 4. Laffel LM et al. Effect of continuous glucose monitoring on glycemic control in adolescents and young adults with type 1 diabetes: a randomized clinical trial. JAMA. 2020;323:2388-2396. 5. Data presented at ADA Virtual June 12-16, 2020. Thabit H et al. Comparison of Dexcom G6 RT-CGM with self-monitoring blood glucose in young people with type 1 diabetes - The MILLENNIAL Study. 6. Beck RW et al. Effect of continuous glucose monitoring on glycemic control in adults with type 1 diabetes using insulin injections: The DIAMOND randomized clinical trial. JAMA. 2017;317(4):371-378. 7. Beck RW et al. Continuous glucose monitoring versus usual care in patients with type 2 diabetes receiving multiple daily insulin injections: A randomized trial. Ann Intern Med. 2017;167:365-374.8. Lind M et al. Continuous glucose monitoring vs conventional therapy for glycemic control in adults with type 1 diabetes treated with multiple daily insulin injections: The GOLD randomized clinical trial. JAMA. 2017;317(4):379-387. 9. Data presented at ADA Virtual June 12-16, 2020. Lind et al. Sustained intensive treatment and long-term effects on HbA1C reduction by CGM in persons with type 1 diabetes treated with MDI (SILVER study), 10. Ruedy KJ et al. Continuous glucose monitoring in older adults with type 1 and type 2 diabetes using multiple daily injections of insulin: Results from the DIAMOND trial. J Diabetes Sci Technol. 2017;11:1138-1146. 11. Pratley RE et al. Effect of continuous glucose monitoring on hypoglycemia in older adults with type 1 diabetes: A randomized clinical trial. JAMA. 2020;323:2397-2406. 12. Data presented at ADA Virtual June 12-16, 2020. WISDOM 6-month extension data.


Dexcom Clarity

What is Dexcom Clarity?


Patients and HCPs can access clinically relevant glucose patterns, trends, and statistics via a range of interactive reports, at no cost to either of you.*-‡



Patient access




Healthcare provider access




^{*}Register for Dexcom Clarity at Clarity.dexcom.com/professional/registration †An internet connection is required for patients to send their glucose data to Dexcom Clarity via a compatible smart device: dexcom.com/compatibility. Healthcare providers will only be able to view a patient's glucose data if the patient elects to share it with them through Dexcom Clarity.

Dexcom Clarity Data Access is Simple




Dexcom Clarity Data Access is Simple



Your Dexcom Clarity Clinic Account


Create and Start Connecting With Your Patients

Recommend Download Apps to Start and Share




- If unable to download either app prior to visit, recommend patient bring in their app store password to get assistance at their visit (typically their phone ID)
- Dexcom G6 and Dexcom Clarity app: same username and password

Add New Patients Quickly



Set up Real-Time Sharing Indefinitely




Invite Patient To Share Data

- After clicking Share data option: click invite, print or email
- Patient needs to have the Dexcom Clarity app on their phone or have an account on their computer

Invite this patient to share data

If the patient accepts, their personal Dexcom CLARITY account and your clinic's account will automatically share data between them.



Please select one of the following options.

Print an InvitationEmail an Invitation

Invite Cancel

Share Data With Clinic

Ask patient to enter code in their Dexcom Clarity account under Profile

Patient Name: john d. Dexcom CLARITY

Generated at: Aug 2, 2021 10:53 PM



Then Authorize Sharing, accept code (not generate)

Share data with your clinic

Smith Diabetes Care LLC invites you to share your data using Dexcom CLARITY.

Dexcom CLARITY software captures your continuous glucose monitoring (CGM) data so you and your clinic can view patterns, trends and statistics anytime, anywhere.

Your sharing code* WLRD-HDHX-DBZD

Enter this code at https://clarity.dexcom.com/share


*Expires: September 2, 2021




Patient Enters Code to Share Data with Healthcare Providers

To begin sharing data, the user will:


- Log into the Dexcom Clarity app with Dexcom login
- Tap Profile > Authorize
 Sharing> Accept Invitation
- Enter sharing code and date of birth





Interpret Dexcom Clarity Data and Reports

Core CGM Metrics and Goals for Time in Range (TIR)^{1,2}




^{1.} Battelino T et al. Diabetes Care. 2019;42(8):1593-1603. 2. American Diabetes Association. Diabetes Care 2021;44(Suppl. 1):S73—S84 | https://doi.org/10.2337/dc21-S006. *Includes percentage of values >250 mg/dL **Includes percentage of values >54 mg/dL

AGP Report

The AGP is an AACE/ADA-recommended, standardized report for retrospective CGM interpretation created by the International Diabetes Center. This report has 3 distinct sections that:


- Summarize glucose values to help assess the overall quality of glucose control
- 2 Show variability in the mean glucose and patterned areas of highs and lows
- Show single-day glucose values to help identify patterns and progress



Dexcom Clarity offers nine reports that can support your in-person or remote conversations—all of which are generated from ADA-backed, industry-standard metrics.




Overview: contains key metrics to help address chief concerns; also allows you to bill for CGM review.






Logan had a pattern of nighttime highs

Logan had a pattern of significant highs between 3:15 AM and 3:45 AM. 7 high events contributed to this pattern. None of the contributing events were rebound highs.








Patterns: identified patterns begin discussions on what, why and how to address issues.

✓


Trends: displays a patient's glucose trends at different times of day over a selected date range.






Overlay: each graph contains up to 7 days of all sensor CGM data points to help visualize patterns and individual events.






Daily view: allows users to analyze all glucose values over individual days, as well as isolated, patient-entered events for each day.



Compare: displays two date ranges of a patient's values to compare side-by side.





Statistics: focus on metrics and glucose control.

Time in Range can be compared across days or times

to identify issues.



Rapid Data Interpretation with the DATAA Model

Review of DATAA Model



Download or view data in Clarity clinic



Review time below range and hypoglycemia, discuss potential reasons and realistic solutions



Review progress towards time-in-range goals



Review time above range and identify possible causes, solutions, and adjustments to self-management







Discuss potential changes in the treatment plan

Using DATAA to Quickly Review Dexcom Clarity



Average Glucose 162_{ma/dL} Standard Deviation 7.2% 54 mg/dL





Billing and Reimbursement

2021 Continuous Glucose Monitoring (CGM) Coding Reference



Codes / Description	Medicare Physician Office Fee Schedule	Medicare Outpatient Diabetes Center	Private Payer (2019 Averages)	Relative Value Unit (RVU) Non-Facility
CGM Services				
CPT 95249 (Personal CGM - Startup/Training)				
Ambulatory continuous glucose monitoring of interstitial tissue fluid via a subcutaneous sensor for a minimum of 72 hours; patient-provided equipment, sensor placement, hook-up, calibration of monitor, patient training, and printout of recording. Bill only once during the time period that the patient owns the device.	\$58.62	\$55.66 APC 5733	\$127	1.68
CPT 95250 (Professional CGM)				
Ambulatory continuous glucose monitoring of interstitial tissue fluid via a subcutaneous sensor for a minimum of 72 hours; physician or other qualified health care professional (office) provided equipment, sensor placement, hook-up, calibration of monitor, patient training, removal of sensor, and printout of recording. Do not bill more than 1x/month.	\$157.37	\$118.74 APC 5012	\$304	4.51
CPT 95251 (CGM Interpretation)				
Ambulatory continuous glucose monitoring of interstitial tissue fluid via a subcutaneous sensor for a minimum of 72 hours; analysis, interpretation and report. Do not bill more than 1x/month.	\$35.59	Paid under physician fee schedule	\$96	1.02

The reimbursement information provided is intended to assist you with billing for your services related to continuous glucose monitoring (CGM).

It is intended for informational purposes only and is not a guarantee of coverage and payment. CMS-1734-F Medicare Physician Fee Schedule Final Rule 2021.


CMS-1736-FC; Medicare Outpatient Prospective Payment System Final Rule 2021. Fee schedules are national averages and are not geographically adjusted.

PMIC Medical Fees in the United States 2020. Numbers provided are the median of the Usual and Customary (UCR) charges. Note that these are charges and not actual reimbursed amounts.


CPT 2021 Professional Edition. Chicago, IL: American Medical Association.

Dexcom Clarity: COPY/PASTE Feature for Electronic Health Records

1. Copy in the Overview Page



2. Checkmark will appear when copied



3. Paste data into EHR

Time in Range Always Accurate Very High: 2% Date of Birth: 1979-12-26 High: 26% Generated at: Mon, Jun 7, 2021 8:17 PM CDT In range: 71% Reporting period: Tue May 25, 2021 - Mon Jun 7, 2021 Low: 0% Very Low: 0% Glucose Details Average glucose: 157 mg/dL Target Range Standard deviation: 43 mg/dL 70-180 mg/dL GMI: 7.1% **CGM Details** Sensor usage: 100% Days with CGM data: 14/14

Expanded coverage and lower costs¹ help support more of your insulin-using patients.

Dexcom users report the lowest out-of-pocket costs,¹ and Medicare copay is the same price as that of other CGM brands.²

Follow these two steps:

- **1.** Enter 'Dexcom G6' in your e-prescribing software and select the quantities and refills for each component.
- 2. Sign, order, and submit prescription to ASPN or your patients' preferred local pharmacy.







Dexcom G6 sensor

Dexcom G6 transmitter

Dexcom G6 receiver

Prescription Options	Product NDC Code	Quantity	Refills
Dexcom G6 sensor	08627-0053-03	3 sensors per box	Every 30 days
Dexcom G6 transmitter	08627-0016-01	1	Every 3 months
Dexcom G6 receiver	08627-0091-11	1	Once a year

^{1.} Seagrove Partners Q3 2020 Patient Perspectives Survey. 2020: 36. 2. Centers for Medicare & Medicaid Services, Medicare Coverage of Diabetes Supplies, Services, & Prevention Programs. 2019; 6.

BRIEF SAFETY STATEMENT Failure to use the Dexcom G6 Continuous Glucose Monitoring System (G6) and its components according to the instructions for use provided with your device and available at https://www.dexcom.com/safety-information and to properly consider all indications, contraindications, warnings, precautions, and cautions in those instructions for use may result in you missing a severe hypoglycemia (low blood glucose) or hyperglycemia (high blood glucose) occurrence and/or making a treatment decision that may result in injury. If your glucose alerts and readings from the G6 do not match symptoms or expectations or you're taking over the recommended maximum dosage amount of 1000mg of acetaminophen every 6 hours, use a blood glucose meter to make diabetes treatment decisions. Seek medical advice and attention when appropriate, including for any medical emergency.

Strategies to Implement Dexcom G6 and Dexcom Clarity In Your Practice

Team Roles & Workflows

Enlist Your Team to Support Use

Support Staff



- Patient Dexcom **Clarity Assistance**
- Clinic Manager, IT, Quality team: Upload reports

Clinical Staff



- Identify patients during triage, chart prep and report to provider.
- Ordering assistance if needed
- Patient support if needed

HCP



- Identify patients
- Order Dexcom G6 and customize to your patient
- Review Dexcom Clarity Reports and bill interpretation

Dexcom is Here to Support YOU and Your Patients



Support with Dexcom orders and general customer questions

1-888-738-3646

Global Technical Support

Product troubleshooting or replacement inquiries

1-844-607-8398

Available 24 hours a day; 7 days a week

Request a Call Back

Place Your First Order

Need Pharmacy Information

- Submit a Patient Support Request
- Request Sensor Overpatches
- Chat Live with Dexcom Tech Support

Dexcom CARE

Dexcom CGM training, software downloads, and tutorials

1-877-339-2664

Resources



Connect with Global Thought Leaders to Advance Diabetes Technology


SIGMA

Study of Improved **Glucose Monitoring** and Assessment

Join SIGMA to learn about:

- Expert Presentations
- Clinical Evidence
- Diabetes Technology Resources
- Coverage and Reimbursement
- Latest News





If you are not already a member, we invite you to learn more about SIGMA or request membership at www.cgmonitoring.net

Dexcom G6 Safety Statement

Failure to use the Dexcom G6 Continuous Glucose Monitoring System (G6) and its components according to the instructions for use provided with your device and available at https://www.dexcom.com/safety-information and to properly consider all indications, contraindications, warnings. precautions, and cautions in those instructions for use may result in you missing a severe hypoglycemia (low blood glucose) or hyperglycemia (high blood glucose) occurrence and/or making a treatment decision that may result in injury. If your glucose alerts and readings from the G6 do not match symptoms or expectations or you're taking over the recommended maximum dosage amount of 1000mg of acetaminophen every 6 hours, use a blood glucose meter to make diabetes treatment decisions. Seek medical advice and attention when appropriate, including for any medical emergency.

The web-based Dexcom Clarity software is intended for use by both home users and healthcare professionals to assist people with diabetes and their healthcare professionals in the review, analysis, and evaluation of historical CGM data to support effective diabetes management. It is intended for use as an accessory to Dexcom CGM devices with data interface capabilities. Caution: The software does not provide any medical advice and should not be used for that purpose. Home users must consult a healthcare professional before making any medical interpretation and therapy adjustments from the information in the software. Caution: Healthcare professionals should use information in the software in conjunction with other clinical information available to them. Caution: Federal (US) law restricts this device to sale by or on the order of a licensed healthcare professional.

Dexcom. Dexcom G6, Dexcom Share, and Dexcom Clarity are registered trademarks of Dexcom, Inc. in the United States and/or other countries.

Dexcom, Inc. I 6340 Sequence Drive I San Diego, CA 92121

Technical Support: 1-877-339-2664 I www.dexcom.com

©2021 Dexcom, Inc. All rights reserved.

THANK YOU!!

Questions?